Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-16

Study Completion Date

2023-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process. This study aimed to determine the role of fecal calprotectin (FCP) as an inflammatory biomarker in course of obesity and NAFLD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease

NCT02658786

HBV NAFLD HCV

WITHDRAWN

Is Lymphocyte Subtype Important for Acute Pancreatitis Severity?

NCT04502940

Pancreatitis Lymphocytic Infiltrate Immune System Diseases

COMPLETED

Identification of Liver Fibrosis Biomarkers

NCT06819917

Non-alcoholic Fatty Liver Non-Alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis

NOT_YET_RECRUITING

Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis

NCT03842748

Non-alcoholic Fatty Liver Disease

UNKNOWN

Fatty Acids, Genes and Microbiota in Fatty Liver

NCT02148471

Nonalcoholic Fatty Liver Disease Steatosis Nonalcoholic Steatohepatitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity is a significant public health issue worldwide. With the increasing prevalence of obesity, the prevalence of metabolic syndrome in adolescents is also on the rise. Non-alcoholic fatty liver disease (NAFLD), a major cause of chronic liver disease, is the hepatic component of metabolic syndrome. The prevalence of NAFLD is not precisely known, but in some studies, it is between 22.5% and 52.8% in children with obesity, constituting 2.6% of all children. Although the mechanisms involved in the development of obesity-related metabolic complications and NAFLD are not well understood, it is believed that intestinal inflammation, changes in the microbiota, and alterations in the gut-liver axis (GLA) may play a role in the development of low-grade chronic inflammation in NAFLD associated with obesity. Fecal calprotectin (FCP), which has become increasingly important in demonstrating intestinal inflammation in recent years, is a widely used test, particularly in the diagnosis and monitoring of inflammatory bowel disease and various gastrointestinal disorders. In our study, the utility of FCP as an inflammatory biomarker in the course of NAFLD in obese adolescents has been investigated. The study was approved by our hospital's ethics committee in 15.11.2022 and another ethics committee approval was taken in 08.06.2023 for title change of study. This study conducted under the Helsinki Declaration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity, Childhood NAFLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Fecal calprotectin samples taken for comparison from healthy adolescents

Group Type EXPERIMENTAL

Fecal Calprotectin Test

Intervention Type DIAGNOSTIC_TEST

Fecal samples are taken fom obese and healthy adolescents for study

Obese group

Fecal calprotectin samples taken from obese adolescents

Group Type EXPERIMENTAL

Fecal Calprotectin Test

Intervention Type DIAGNOSTIC_TEST

Fecal samples are taken fom obese and healthy adolescents for study

Obese + NAFLD group

Fecal calprotectin samples taken from obese adolescents that have NAFLD

Group Type EXPERIMENTAL

Fecal Calprotectin Test

Intervention Type DIAGNOSTIC_TEST

Fecal samples are taken fom obese and healthy adolescents for study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Calprotectin Test

Fecal samples are taken fom obese and healthy adolescents for study

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 10-18 years old healthy adolescents for control group
* Children aged 10-18 years without any additional diseases, BMI\>2 SD, no hepatosteatosis detected by ultrasonography (USG), and alanine aminotransferase (ALT) levels within normal limits were included in the obese group
* Children aged 10-18 years without any additional diseases, BMI\>2 SD, Hepatosteatosis detected by ultrasonography (USG), and alanine aminotransferase (ALT) levels higher than normal limits adjusted for gender were included in the obese + NAFLD group